Dr. Vipin Kumar Yadav is a multidisciplinary scientist currently serving as a Postdoctoral Researcher at the H. Lee Moffitt Cancer Center & Research Institute, USA. He holds advanced degrees in Applied Microbiology and Biological Sciences, having completed his doctoral training at the CSIR–Indian Institute of Toxicology Research, India, and postdoctoral training in Cancer Biology in the United States. His professional experience spans molecular oncology, toxicology, and environmental biotechnology, with significant contributions to understanding nitrosylation-driven resistance in NRAS-mutant melanoma, melanin chemiexcitation in UV-induced DNA damage, and autophagy-mediated mechanisms in KRAS-driven cancers. Dr. Yadav’s research interests lie at the intersection of molecular cancer biology, redox signaling, immunogenic cell death, and bioremediation, with an emphasis on developing integrative therapeutic and environmental strategies to combat genotoxic stress. He possesses strong technical expertise in genome editing, proteomics, cell-based assays, and in vivo tumor modeling. His scientific achievements have been recognized through several national and international fellowships and awards, reflecting his commitment to translational and sustainable research. Overall, Dr. Yadav’s work bridges toxicology and oncology to advance innovative molecular insights and therapeutic solutions for both human health and environmental protection.
-
Peng, S. B., Henry, J. R., Kaufman, M. D., Lu, W. P., Smith, B. D., Vogeti, S., … & Yadav, V. (2015). Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell, 28(3), 384–398.
-
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X. Q., Buchanan, S., Henry, J. R., & Peng, S. B. (2012). Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Journal of Biological Chemistry, 287(33), 28087–28098.
-
Chen, S. H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., … & Peng, S. B. (2016). Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discovery, 6(3), 300–315.
-
Chen, Y., McGee, J., Chen, X., Doman, T. N., Gong, X., Zhang, Y., Hamm, N., Ma, X., … & Yadav, V. (2014). Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS ONE, 9(5), e98293.
-
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., … & Peng, S. B. (2014). The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Molecular Cancer Therapeutics, 13(10), 2253–2263.
-
Yadav, V., & Denning, M. F. (2011). Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Molecular Carcinogenesis, 50(5), 346–352.
-
Atkinson, J. M., Rank, K. B., Zeng, Y., Capen, A., Yadav, V., Manro, J. R., Engler, T. A., … & Peng, S. B. (2015). Activating the Wnt/β-catenin pathway for the treatment of melanoma – Application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3. PLoS ONE, 10(4), e0125028.
-
Yadav, V., Chen, S. H., Yue, Y. G., Buchanan, S., Beckmann, R. P., & Peng, S. B. (2014). Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacology & Therapeutics, 44, [Article/Pages not specified].
-
Yadav, V., Yanez, N. C., Fenton, S. E., & Denning, M. F. (2010). Loss of protein kinase C δ gene expression in human squamous cell carcinomas: A laser capture microdissection study. The American Journal of Pathology, 176(3), 1091–1096.
-
Voris, J. P., Sitailo, L. A., Rahn, H. R., Defnet, A., Gerds, A. T., Sprague, R., & Yadav, V. (2010). Functional alterations in protein kinase C beta II expression in melanoma. Pigment Cell & Melanoma Research, 23(2), 216–224.